Pediatric Syncope: Where Are We Now?
Hang Jin,Junbao Du
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20132944
2014-01-01
Abstract:Syncope is precisely defined as a temporary loss of consciousness due to global cerebral hypoperfusion, often accompanied with loss of muscular tension and the failure to maintain active position. Pre-syncope is a state consisting of transient lightheadedness, loss of or weaker muscle tension, but not accompanied with loss of consciousness. Syncope and pre-syncope are common symptoms occurring in children and adolescents. Girls present more morbidity than boys. And patients with syncope accounted for about 1%-2% of all pediatric patients in the emergency department.1,2 Among medical students at an average age of 20 years, one survey found that about 20% of males and 50% of females reported to have syncope at least once.3 The onset of syncope greatly affects the physical and psychological health of children and adolescents, which is a research hotspot in the field of pediatric cardiology at home and abroad. Pathogenesis of syncope Syncope is a symptom, having various underlying diseases such as autonomic-mediated reflex syncope (AMS), cardiac syncope, and cerebral vascular disease-related syncope. Of them, AMS is the main type, in which vasovagal syncope (VVS) is one of the most common type.4 Great progress has been made in understanding the pathogenesis of AMS. It is known that disturbance of endocrine substances as well as active peptides in the regulation of blood volume, autonomic nervous function, and vascular tension are involved in the pathogenesis of AMS. Endothelium-dependent vascular relaxation is significantly enhanced in pediatric cases of VVS when compared with the control group, suggesting that the endothelium-dependent vascular relaxation might be one of the mechanisms.5 Enhanced endothelium-dependent vascular relaxation and endothelium dysfunction were also present in patients with postural orthostatic tachycardia syndrome (POTS).6 However, the pathogenesis of pediatric AMS has not yet been fully understood and needs further exploration. Clinical characteristics of main underlying diseases of syncope VVS is the most common cause of syncope in children, accounting for about 60% of all pediatric cases. Our study showed that this disease mainly occurred in girls at the age of 11–19 years and is usually induced by the following factors: persistent standing, seeing bleeding, feeling severe pain, under sweltering condition, having hot bath, exercise, and so on. Before the onset, some premonitory symptoms may occur, such as temporary dizziness, inattention, pale face, visual and auditory loss, nausea, vomiting, sweating, and astasis. Head-up tilt test (HUT) is a widely recognized method for the diagnosis and differential diagnosis of this disease.7,8 Recently, we have found that hydrogen sulfide, a novel endogenous gaseous signal molecule, is of great significance in the differentiation between VVS and POTS.9 POTS refer to an obvious increase in heart rate (HR) within 10 minutes in HUT or a marked increase maximum HR, meanwhile accompanied with orthostatic intolerance symptoms, after excluding other underlying diseases causing autonomic nervous system symptoms.6 Recently, some experts suggested a more significant HR increase limit for the diagnosis of POTS.10,11 OH is defined as an obvious fall of blood pressure in HUT or head-up test. As the blood pressure decreases obviously, some symptoms may occur in patients, such as dizziness, syncope, or pre-syncope. Some believe that this disease is mainly caused by autonomic nervous response disorders in patients. In 2012, pediatric orthostatic hypertension (OHT), a new type of orthostatic intolerance in children, and its clinical features were first reported. Sometimes, patients with OHT may experience syncope.12 However, its mechanisms, clinical characteristics, and treatment strategies still need to be further explored. Syncope can be secondary to cardiac problems (cardiac syncope), such as arrhythmia and cardiac structural diseases, which has relatively high risk and sometimes is life-threatening. The corresponding sharply decreased cardiac output causes insufficient blood supply to brain. Studies have found that the plasma brain natriuretic peptide (BNP) level in pediatric patients with cardiac syncope was significantly higher than those with noncardiac syncope. With the help of ROC curve, it was found that plasma BNP level had high diagnostic value in the identification of cardiac syncope and noncardiac syncope in children. When plasma BNP level was higher than 40.65 pg/ml, the sensitivity and specificity for the diagnosis of syncope caused by structural heart disease were 73.9% and 70.0%, respectively. Therefore, plasma BNP is of important value in the differential diagnosis between noncardiac syncope and cardiac syncope in children.13 Diagnostic protocol of syncope Since syncope is a common disease or symptom and some patients have high risk of sudden death, formulating suitable diagnostic procedures for patients with syncope is a great issue attracting much attention of cardiologists. Generally, the diagnostic protocol is divided into two steps. In step 1, all patients underwent initial evaluation for history, physical examination, standing test, and standard electrocardiography. In step 2, priority was given to laboratory tests for possibly cardiogenic syncope, or electroencephalographic examination and brain imaging for suspected neurological diseases, or psychiatric tests for suspected psychiatric diseases. Patients with unexplained syncope underwent HUT. A multicenter-based research in China indicated that the effective rate of this diagnostic protocol was 81.1%, and health economic evaluation found that when compared with traditional diagnostic procedures, the average medical expenses of new diagnostic procedures were decreased, and the time required for diagnosis was obviously shortened, as well as the average hospital stay.14 Treatment of syncope To successfully treat children with AMS attracts a great attention nowadays. For children with syncope, to find etiology is the first step. Non-pharmacological therapies including psychological intervention and maneuvers can be used, in an effort to prevent the symptoms and syncope at the onset of pre-syncope. Then individual treatment is formulated based on the cause. Through health education in children with VVS, including increasing the salt and water intake, symptoms could be relieved in 20% of pediatric patients. Since the supplement of salt and fluid intake is relatively safe and easily accepted by children and parents, in the initial treatment for children with VVS, it is very worthy of recommendation. Twenty-four hours urine sodium analysis could be used as a predictor for the effectiveness of salt and fluid intake therapy in children with POTS.15 β-receptor blockers are commonly used drugs in the treatment of children with VVS. Our team investigated the curative effect of metoprolol on children with VVS. Dividing the HUT-positive children with VVS into two groups, metoprolol treatment group and control group, it was found that metoprolol therapy was effective.16 However a recent randomized double-blind placebo-controlled trial and a long-term follow-up study found that the curative effect of β-receptor blockers in the treatment of patients with VVS is not sure.17,18 In view of the above situation, we compared the hemodynamic changes in HUT between patients with or without response to metoprolol treatment and found that for those with obviously increased HR (30 times/min more than the basic HR) before positive reaction in HUT, the application of â-receptor blockers was more effective, thus putting forward the individualized treatment strategy. Through meta-analysis, we also believed that â-receptor blocker is an effective drug for the treatment of VVS, but whose curative effect remained to be further analyzed and explored through large-scale, more accurate, and strict multi-center randomized controlled trial.19 α-receptor agonists were used for AMS by increasing peripheral vascular contraction and reducing venous blood volume. We first tested midodrine hydrochloride in the treatment of VVS in children. The results showed that midodrine hydrochloride was effective for the treatment of children with VVS.20 Through meta-analysis, we also found that á-receptor agonists were effective to treat VVS.21 Recently it was found that midodrine hydrochloride is effective in the treatment of POTS in children, whose effectiveness and cure rate reached 89.47% and 68.42%, respectively.16 To explore new biomarkers for predicting the therapeutic response of patients with POTS, it was revealed that the predictive value of mid-regional pro-adrenomedullin (MR-proADM) was found for the curative effect of á1-receptor agonists on POTS in children. Studies showed that the plasma MR-proADM content in children with POTS was significantly higher than normal controls. For midodrine hydrochloride therapy, the plasma MR-proADM content of those patients with good response was significantly higher than those with poor response. ROC curve analysis showed that when plasma MR-proADM was used for predicting the therapeutic response of patients with POTS, the area under the curve was 0.879, and the 95% confidence interval was (0.761, 0.761) with the sensitivity and specificity of curative effect prediction being 100% and 71.6%, respectively. Based on these results, MR-proADM could serve as an important predictor for the drug selection in the treatment of POTS in children.22 Recently, we found that erythrocytic hydrogen sulfide could also serve as a useful predictor of therapeutic response to midodrine hydrochloride in POTS of children.23 Randomized controlled prospective studies have been carried out in Europe and North American countries on pacemaker therapy in the treatment of VVS in adult patients, whose conclusions were not very consistent.24 There are few reports about the application of pacemaker therapy in children with VVS. In short, nowadays, great progress has been made in the clinical research of pediatric patients with VVS and related diseases. However, we should further strengthen the research on the pathogenesis of VVS and related diseases. We need to continue strengthen the research on the clinical characteristics and timely diagnosis of pediatric syncope including POTS, VVS, OH, and OHT with relatively low costs. A multicenter-based prospective evaluation on the individualized treatment and prevention of POTS and VVS is strongly needed. (Received March 26, 2014) Edited by Chen Limin